Rebetol relates to synthetic analogues of nucleosides with pronounced antiviral activity.
The active component of Rebetol is ribavirin which penetrates virus-infected cell, where it undergoes phosphorylation to mono-, di – and triphosphates. Among all the metabolites of ribavirin, its triphosphate has the greatest antiviral activity. Inhibiting IMF, Rebetol reduces the amount of intracellular GTP, which is involved in the synthesis of RNA and specific proteins of the virus. Impaired replication of viral cells provides a significant reduction in viral load. The specificity of action of Rebetol is an exceptional violation of the synthesis of RNA virions, while the RNA of healthy cells intact to the drug can be bought on our website.
Pegylated alpha-2b potentiates the antiviral activity of Rebetol by enhancing the phosphorylation of ribavirin, which has a positive effect on the histological picture of the liver.
Apart from a pronounced destructive action on HCV, Rebetol is effective against diseases caused by herpes simplex virus, virus of Marek’s illness. RNA viruses have a pronounced sensitivity to the drug: influenza A, b, paramyxovirus (para-influenza, epidemic parotitis, Newcastle disease), reoviruses, RNA tumoral viruses.
After oral administration Rebetol is rapidly absorbed in the gastrointestinal tract. The bioavailability of its active component ribavirin reaches 45%. Ribavirin is accumulated in the erythrocytes, which is the secret of the respiratory tract and plasma. During the prolonged use of Rebetol, the active ingredient in high concentration is noted in the cerebrospinal fluid. A large part of ribavirin and its metabolites are excreted by the kidneys, about 10% – with feces.
Indications for use
Rebetol is prescribed to adults and children older than 3 years with chronic hepatitis caused by a virus, only as part of combined treatment with Alfa-2b IF or pegylated counterpart.
Adult patients, who have not previously received alpha-IF, are prescribed Rebetol with Alfa-2b IF in case of the disturbed renal function with high level of Alt and high level of serum HVC-RNA. Rebetol is also used by patients with compensated cirrhosis with or without concomitant HIV infection.
Teenagers and children older than 3 years, who have not previously received Alfa-2b IF, are prescribed Rebetol with Alfa-2b IF in the case of absence of decompensated liver failure and detection of HVC-RNA in the plasma.
Rebetol is prescribed to patients who have been already previously treated with alpha-2b IF with a positive clinical effect on prior combination therapy, but with recurrence. Also, Rebetol is used by individuals after failure of prior monotherapy with Alfa-2b IF (its pegylated analogue) or in combination that makes treatment so expensive.
The method of reception
Rebetol in the form of capsules can be bought on our website and taken twice a day during a meal for best absorption. The daily amount of the drug is calculated from the actual body weight of the patient. Therapy with the drug is conducted by an experienced specialist with a combination of alpha-2b IF or its pegylated analogue.
Patients with body weight less than 65 kg take 800 mg of Rebetol per day, people with the actual weight of 65-80 kg take the dosage of 1000 mg per day, 2 capsules taken in the morning, the remaining 3 are taken in the evening. 6 capsules of Rebetol are taken by patient with body weigh in the range of 80-105 kg. Patient with body weight more than 105 kg are recommended to take 7 capsules of the drug, 3 of them are taken in the morning, and the remaining 4 capsules are taken in the evening.
Combination therapy with Rebetol and peg-if Alfa-2b.
In case of inadequate virological effect after 1-3 months of treatment, patients, who are infected with HCV of the 1st genotype, with the same level of HCV-PHK, are recommended to stop treatment with Rebetol, as the probability of a positive clinical response is low.
When you achieve a positive virological response in the 3 month of therapy with Rebetol, you should continue treatment for another 9 months.
In case of reducing the amount of HCV-PHK of patients with HCV at least by 2 grades compared to the previous period, they are recommended to continue therapy with Rebetol to 48 weeks in total, in case of dynamic serological monitoring the level of HCV-PHK. In the case of a regular increase in the concentration of HCV-PHK, Rebetol is canceled.
Patients with the 2nd and 3rd genotype with HCV hold the duration of therapy with Rebetol during 24 weeks. The only exception is patients with HIV co-infection when treatment is carried out for 48 weeks.
Infected patients with the 4th genotype of the virus of hepatitis hold therapy with Rebetol for 48 weeks.
The duration of Rebetol therapy of children and adolescents is the same as in case adults, and depends on the genotype of the virus of the infected patient.